Ginkgolide B NEW
Price | $57 | $97 |
Package | 25mg | 50mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-19 |
Product Details
Product Name: Ginkgolide B | CAS No.: 15291-77-7 |
Purity: 99.77% | Supply Ability: 10g |
Release date: 2024/11/19 |
Product Introduction
Bioactivity
Name | Ginkgolide B |
Description | Ginkgolide B (BN-52021) is a PAFR antagonist(IC50=3.6 μM) isolated from Ginkgo biloba. |
In vitro | Oral administration of Ginkgolide B (50 mg/kg) before ischemia notably reduces neuronal damage in the hippocampus of rats. In a mouse model of focal transient ischemia, a 30-minute pretreatment with Ginkgolide B (100 mg/kg, s.c.) diminishes the area of infarction. Additionally, in animals anesthetized with pentobarbital or ethyl carbamate, Ginkgolide B, administered either intravenously (1 mg/kg) or orally (10 mg/kg), inhibits bronchoconstriction and increases hematocrit. |
In vivo | Ginkgolide B effectively inhibits platelet-activating factor (PAF) receptors. In cystic cells, it modifies the Ras/MAPK signaling pathway, inducing cell differentiation. In EPC cells, Ginkgolide B promotes cell proliferation and endothelial gene expression by inducing the phosphorylation of eNOS, Akt, and p38, significantly enhancing vascular endothelial growth factor (VEGF)-induced migration responses. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 60 mg/mL (141.38 mM) Ethanol : 10.6 mg/mL (25 mM) |
Keywords | BN52021 | Apoptosis | inhibit | Ginkgolide B | Inhibitor | BN 52021 | Endogenous Metabolite |
Inhibitors Related | Stavudine | Potassium gluconate | 5-Fluorouracil | Dextran sulfate sodium salt (MW 4500-5500) | Sodium 4-phenylbutyrate | Acetaminophen | Sorafenib | Tributyrin | Formamide | Oleamide | Glycerol | Oleic acid |
Related Compound Libraries | Anti-Tumor Natural Product Library | Terpene Natural Product Library | Bioactive Compound Library | Flavor Compound Library | Selected Plant-Sourced Compound Library | Inhibitor Library | Natural Product Library for HTS | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Food as Medicine Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/25kg |
Shaanxi Haibo Biotechnology Co., Ltd
|
2023-08-21 | ||
$120.00/1kg |
Hebei baicao biology science and technology co., ltd
|
2022-05-09 | ||
$0.00/20mg |
Shanghai Standard Technology Co., Ltd.
|
2019-10-25 | ||
$1.00/1KG |
VIP7Y
|
Career Henan Chemical Co
|
2018-12-25 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY